95420-73-8

Basic information

• Product Name: Benzoic acid, 2-hydroxy-4-(methylthio)-, methyl ester
• CAS NO: 95420-73-8
• Molecular Formula: C9H10O3S
• Molecular Weight: 198.243
• Mol File: 95420-73-8.mol

Chemical Properties

• CAS DataBase Reference: Benzoic acid, 2-hydroxy-4-(methylthio)-, methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Benzoic acid, 2-hydroxy-4-(methylthio)-, methyl ester(95420-73-8)
• EPA Substance Registry System: Benzoic acid, 2-hydroxy-4-(methylthio)-, methyl ester(95420-73-8)

Safety Data

• Hazardous Substances Data: 95420-73-8(Hazardous Substances Data)

Upstream product

• 3463-03-4 3-methylsulfanylphenol 
• 67-56-1 methanol 
• 67127-67-7 2-hydroxy-4-(methylthio)benzoic acid 
• 77-78-1 dimethyl sulfate 

Downstream Products

• 89075-36-5 2-(4-Methanesulfinyl-2-propoxy-phenyl)-3H-imidazo[4,5-c]pyridine 
• 89075-29-6 2-(4-Methylsulfanyl-2-propoxy-phenyl)-3H-imidazo[4,5-c]pyridine 
• 95420-75-0 4-(methylthio)-2-n-propoxybenzoic acid 
• 95420-74-9 4-(methylthio)-2-n-propoxybenzoic acid methyl ester 

Relevant articles and documents

ANTITHROMBOTIC ETHERS

This application relates to a compound of formula I (or a prodrug thereof or a pharmaceutically acceptable salt of the compound or prodrug thereof) as defined herein, pharmaceutical compositions thereof, and its use as an inhibitor of factor Xa and/or thrombin, as well as a process for its preparation and intermediates therefor (I).

Structure-activity relationships of arylimidazopyridine cardiotonics: Discovery and inotropic activity of 2-[2-methoxy-4-(methylsulfinyl)phenyl]-1H-imidazo[4,5-c]pyridine

Recently several noncatecholamine, nonglycoside cardiotonic drugs have been discovered that possess both inotropic and vasodilator activities in experimental animals and man. Prototypical compounds include amrinone, sulmazole, and fenoximone. We investigated the structural requirements necessary for optimal inotropic activity in a series of molecules containing a heterocyclic ring fused to 2-phenylimidazole and discovered that 2-phenylimidazo[4,5-c]pyridines were generally 5-10-fold more potent than analogous 2-phenylimidazo[4,5-b]pyridines (e.g., sulmazole) or 8-phenylpurines. Furthermore, all imidazo[4,5-c]pyridine analogues we tested were orally active; in contrast, only one of the imidazo[4,5-b]pyridine derivatives, sulmazole, was significantly active. One of several highly active compounds in the [4,5-c] series was 50 (LY175326, 2-[2-methoxy-4-(methylsulfinyl)phenyl]-1H- imidazo[4,5-c]pyridine hydrochloride). The structure-activity relationship of this series is presented and compared to that of the imidazo[4,5-b]pyridine and purine series.